drugset / Trial / NCT02812056
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of alisertib and TAK-228 that can be given to participants with advanced solid tumors that are associated with HPV. Researchers also want to learn if the study drug combination can help to control advanced solid tumors.
Timeline
- Start
- 2016-09
- Primary completion
- 2021-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alisertib | Small molecule | 30 mg | Oral |
| Subject | Sapanisertib | Small molecule | 1 mg | Oral |